Title : Cerebroproteins neuroprotective edge: Revolutionizing recovery in head injury patients
Abstract:
Head injury is a leading cause of morbidity and mortality worldwide. Neuroprotective agents like Cerebroprotein, a peptide-based drug with neurotrophic and neuroprotective effects, have shown potential in enhancing recovery and mitigating secondary brain injury. This study evaluates Cerebroprotein's efficacy in patients with traumatic brain injury (TBI). To determine the impact of Cerebroprotein on neurological outcomes and functional recovery in head injury patients. A prospective study was conducted on 50 patients with moderate to severe head injuries (GCS 6–12). Patients were divided into two groups: the intervention group received Cerebroprotein (30 mL IV daily for 5 days), while the control group received standard care. Neurological and functional outcomes were assessed using the Glasgow Outcome Scale-Extended (GOS-E) and Barthel Index at baseline, 1 month, and 2 months post-treatment. At 2 months, the intervention group showed significantly improved GOS-E scores and Barthel Index compared to controls (p<0.05). Cerebroprotein was well-tolerated with no major adverse effects, reinforcing its neuroprotective and neurorestorative role in TBI management. Cerebroprotein improves neurological and functional recovery in head injury patients, advocating its inclusion in TBI management protocols. Further studies are warranted to confirm these findings
